🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets

    Ningbo Cancer Hospital

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  3. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  4. Xtandi - 40 mg soft capsules, Xtandi - 40 mg soft capsules, TALAZOPARIB, Xtandi 40 mg soft capsules, TALAZOPARIB, Xtandi - 40 mg soft capsules, Talazoparib placebo

    Pfizer Australia Pty Ltd

    Metastatic Castration-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  7. YiQiFang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 3 small molecule completed

    2 trials

  8. ZYTIGA 250 mg tablets, Placebo to match (PTM) AZD5305 film-coated tablets, Saruparib, ZYTIGA 500 mg film-coated tablets

    AstraZeneca AB

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  9. ZYTIGA 250 mg tablets, ZYTIGA 500 mg film-coated tablets, Apalutamide placebo, JNJ-56021927, PREDNISONE, -

    Lacuna Pharma Pty Ltd

    Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  10. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  11. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive Breast Cancer

    phase 3 small molecule active

    1 trial

  12. Zelenectide Pevedotin, BT8009, PEMBROLIZUMAB, AVELUMAB, CISPLATIN, CARBOPLATIN, GEMCITABINE

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  13. Zimberelimab

    Arcus Biosciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  14. Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. Zoladex 3,6 mg implante en jeringa precargada, Decapeptyl semestral 22,5 mg polvo y disolvente para suspensión de liberación prolongada inyectable., Eligard semestral 45 mg polvo y disolvente para solución inyectable., Bicalutamida Aristo 50 mg comprimidos recubiertos con película EFG

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  16. Zoledronic acid

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  17. Zometa 4 mg/100 ml solution for infusion

    Ningbo Cancer Hospital

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

  18. [18F]-AlF-FAPI-74

    Disc Medicine

    Advanced gastric cancer

    phase 3 small molecule active

    1 trial

  19. a patient self-reporting applet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer Pain

    phase 3 other active

    1 trial

  20. bexarotene

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  21. brigatinib

    Takeda

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials

  22. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  23. canakinumab

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials

  24. cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources